<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>资本估值逻辑 on AI内参</title>
    <link>https://www.neican.ai/tags/%E8%B5%84%E6%9C%AC%E4%BC%B0%E5%80%BC%E9%80%BB%E8%BE%91/</link>
    <description>Recent content in 资本估值逻辑 on AI内参</description>
    <generator>Hugo</generator>
    <language>zh-cn</language>
    <lastBuildDate>Mon, 27 Jul 2026 12:40:03 +0800</lastBuildDate>
    <atom:link href="https://www.neican.ai/tags/%E8%B5%84%E6%9C%AC%E4%BC%B0%E5%80%BC%E9%80%BB%E8%BE%91/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>药片的炼金术：AI制药如何度过“临床”这一道鬼门关？</title>
      <link>https://www.neican.ai/insights/article-20260727124003055-0/</link>
      <pubDate>Mon, 27 Jul 2026 12:40:03 +0800</pubDate>
      <guid>https://www.neican.ai/insights/article-20260727124003055-0/</guid>
      <description>AI制药行业正经历从技术驱动到价值交付的结构性转型，临床开发的临床合规性与运营效率已成为衡量商业价值的新标尺。这一转变标志着行业进入了以“管线质量”为核心的中场战事，谁能实现全流程的数智化闭环，谁便能在全球创新药竞争中脱颖而出。</description>
    </item>
  </channel>
</rss>
